• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis
【24h】

Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis

机译：依那西普（Enbrel）治疗青少年特发性关节炎

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Juvenile idiopathic arthritis (JIA) is a relatively common multidimensional and heterogeneous chronic disease of childhood. Children with JIA are at risk for significant morbidity in terms of joint damage, impairments in physical function and health-related quality of life. Outcomes for children with JIA have significantly improved with the use of biologic therapies in the past 15 years, with the most clinical experience being with etanercept. Areas covered: Basic pharmacokinetic and pharmacodynamic data for etanercept will be highlighted. This article will review the clinical trials and open-label registry data for the efficacy and safety of etanercept for use in JIA. Expert opinion: Etanercept is very effective for the treatment of JIA. Data from clinical trials and open-label studies support its clinical efficacy in 80% of patients which appears to be sustained over several years for the majority of treated patients. The safety profile is also acceptable with a serious adverse event rate of 0.03-0.12 per patient-year. Further research is needed to evaluate any possible link between biologic therapy, JIA and malignancy, to obtain more long-term safety data, and to document improvements in quality of care and cost-benefit for associated with biologic therapies which may additionally assist in access to these medications. Further, identification of potential clinical or laboratory markers allowing for prediction of response and timing of starting and cessation of this biologic therapy are urgently required.
机译：简介：少年特发性关节炎（JIA）是一种相对常见的多维，异质性儿童慢性疾病。患有JIA的儿童在关节损伤，身体机能受损和与健康相关的生活质量方面有高发病率的风险。在过去的15年中，使用生物疗法使JIA儿童的结局有了显着改善，其中临床经验最多的是依那西普。涵盖的领域：依那西普的基本药代动力学和药效动力学数据将突出显示。本文将回顾依那西普用于JIA的疗效和安全性的临床试验和开放标签注册数据。专家意见：依那西普对JIA的治疗非常有效。来自临床试验和开放标签研究的数据支持其在80％的患者中的临床疗效，对于大多数接受治疗的患者而言，这似乎可以持续数年。安全性也可以接受，严重不良事件发生率为0.03-0.12 /患者/年。需要进一步的研究来评估生物治疗，JIA和恶性肿瘤之间的任何可能联系，以获得更多的长期安全性数据，并记录与生物治疗相关的护理质量和成本效益方面的改善，这可能另外有助于获得这些药物。此外，迫切需要鉴定潜在的临床或实验室标志物，以预测该生物疗法的反应以及开始和停止的时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号